The INSPECT study is coordinated by a core team of clinicians and scientists from the department of Human Genetics at the Radboud university medical center (Radboudumc) in Nijmegen, the Netherlands.
The Radboudumc is a recognized expertise center for PHTS, including identification, counselling and surveillance of PHTS patients. PHTS patients throughout the Netherlands are referred to the Radboudumc.
Prof. Nicoline Hoogerbrugge, MD is professor of Hereditary Cancer at the Department of Human Genetics at Radboud University Medical Center, the Netherlands. She is a specialist in the recognition, diagnosis and treatment of hereditary cancer. Since 2017, she is chairing the European Reference Network Genetic Tumour Risk Syndromes (ERN GENTURIS).
Prof. dr. Nicoline Hoogerbrugge is one of the principal investigators of the INSPECT study.
Dr. Janet Vos is an epidemiologist. Her research focuses on identification and risk assessment of familial and hereditary cancer syndromes. She is chairing the Research Task Force ‘Research’ of the European Reference Network Genetic Tumour Risk Syndromes (ERN GENTURIS) and coordinating the European GENTURIS registry. She is coordinator of the Radboud biobank Genetics and Rare Diseases, including the biobank PTEN Hamartoma Tumour Syndrome. Dr. Janet Vos is one of the principal investigators of the INSPECT study and she is coordinating the INSPECT study.
Dr. Janneke Schuurs-Hoeijmakers is a clinical geneticist at the Department of Human Genetics at the Radboud University Medical Center. She is working in the oncogenetics team, with special interest in PHTS. Immunogenetics is another focus of her clinical work.
Katja Verbeek obtained her master’s degree in Health Sciences at the Vrije Universiteit Amsterdam. She works as data manager for the INSPECT study on data collection and database development, and she sends out the study information and questionnaire to study participants.
Linda Hendricks obtained her master’s degree in Biomedical Sciences at the Radboud University, Nijmegen, the Netherlands. She currently works as a PhD candidate at the Department of Human Genetics. In her research she focusses on unravelling the cancer risk and prognosis for patients diagnosed with PHTS.
Meggie Drissen obtained her master’s degree in Biomedical Sciences at the Radboud University in Nijmegen. During her PhD research, she will study the clinical spectrum of PHTS. The goal is to identify ways to improve recognition of PHTS. She will also investigate what kind of care is most appropriate when a patient has been diagnosed with PHTS.
The core team works together with clinicians and scientist in other hospitals from various countries.
‘European Reference Network on Genetic Tumour Risk Syndromes’ (ERN GENTURIS). This partnership consists of European doctors working at centers specializing in rare genetic disorders and hereditary cancer syndromes, such as PHTS.
Several centers of ERN GENTURIS, and centers with which they collaborate, participate in the INSPECT study.
We are always open to extending our INSPECT study network. Please contact us via the contact form if you work in a non-affiliated center and would like to include patients, or if you would like to get more information.
Currently we work together with several centers from European countries. These countries are blue colored on the map below.
The darker the blue color, the greater the expected contribution in patient numbers.